LFST at a glance
LifeStance Health Group, Inc. (LFST, SEC CIK 1845257) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on September 11, 2026 and Form 4 insider filings as recently as September 24, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), LifeStance Health Group, Inc. (LFST) reported revenue of $1.4 billion (up 13.9% from FY2024) and net income of $9.7 million.
- As of June 30, 2026, 32 institutional investment managers tracked by SignalX reported holding LifeStance Health Group, Inc. (LFST) shares worth $1.8 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by TPG GP A, LLC on September 11, 2026 of 18,409,705 shares at $12.29 per share.
- In the last 90 days, LFST insiders reported 0 open-market purchases ($0) and 8 open-market sales ($378.8M) on Form 4, a net sale of $378.8M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $1.4B
- +13.9% vs prior year
- Insiders · 90 days
- 0 buys · 8 sells
- Net −$378.8M
- 13F holders
- 32 funds
- $1.8B · +1 vs prior quarter
- Latest 8-K
- Sep 11, 2026
- Item 8.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Nationwide outpatient mental healthcare platform employing 8,040 clinicians across 33 states with integrated virtual and in-person care
- Strategic shift: Prioritized virtual visits leading to significant reduction of physical office footprint and closure of underoccupied centers in 2023
- Quantitative metric: 1.0 million unique patients treated in 2025 through approximately 9.0 million visits, with 87% having two or more visits
- Emphasis on integrated care: Over 13 active integrated care programs partnering with primary care and specialists to unify mental and physical healthcare
- Noteworthy fact: 90% of revenue derived from commercial in-network payors, enhancing affordability and access through extensive payor contracts
Risk Factors
- Regulatory risk from the No Surprises Act (effective Jan 1, 2022) causing payment disputes and penalties for billing and provider directory inaccuracies
- Geopolitical/macroeconomic exposure from 29% revenue concentration with UnitedHealthcare (14%) and Elevance Health (15%), risking impact from reimbursement changes
- Operational vulnerability in clinician recruitment and retention amid rising labor costs and potential unionization increasing expenses and turnover
- Competitive threat from emerging AI and machine learning technologies reducing demand for licensed clinician care, impacting patient volumes
- Financial risk from high capital expenditures on new centers leading to margin pressure until patient visits generate revenue
Management Discussion & Analysis
- Cash and cash equivalents $248.6M in 2025 vs $154.6M in 2024; operating cash flow $146.2M in 2025 vs $107.3M in 2024
- Debt outstanding $282.8M in 2025 vs $290.0M in 2024 under 2024 Credit Agreement; compliance with leverage and interest coverage covenants
- Investing cash outflow $36.1M for property and equipment in 2025 vs $21.6M in 2024; financing activities used $16.0M in 2025 vs $9.9M in 2024 due to loan repayments and equity award settlements
- No explicit revenue or profit margins disclosed in excerpt; reported $9.7M net income in 2025 vs $57.4M net loss in 2024 mentioned in cash flow section
- Management expects existing cash sufficient for 12 months; growth, acquisitions, and market expansion are key risks requiring potential additional financing
AI summary of the LFST 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- Ownership concentration: TPG and Summit collectively owned approximately 35.4%, enabling significant influence over board composition and change-of-control decisions
- Nasdaq governance transition: Loss of “controlled company” status triggered a one-year phase-in for independent compensation and nominating committees
- Governance compliance exposure: Full independent-committee compliance required within one year of losing controlled-company status
AI summary of the LFST 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- Underwritten offering of 22,250,000 LifeStance shares by selling stockholders, closing September 11, 2026
- Company received no proceeds, limiting direct balance-sheet benefit from the transaction
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026, released August 6, 2026
- Detailed operating and financial metrics contained in Exhibit 99.1 press release
Item 7.01: Regulation FD Disclosure
- Exhibit 99.2 contains supplemental LifeStance Health Group information under Regulation FD
- Investor-relevant details are provided in the accompanying slide presentation
Item 8.01: Other Events
- New $100 million share repurchase authorization approved August 5, 2026
- Program replaces prior $100 million authorization from February 24, 2026
Item EX-99.1: Item EX-99.1
- Q2 revenue $435.4M, up 26%, with visits up 19% to 2.6M and clinicians up 11% to 8,542
- Net income $23.6M versus $3.8M loss; Adjusted EBITDA $66.0M, up 94%, with margin reaching 15.2%
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Jeffrey Rhodes resigned from the Board and all committees effective July 2, 2026, without reported disagreement
- Three directors appointed, signaling a material Board refresh and committee reallocation
AI summaries of LFST 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for LFST
Don't miss the next LFST filing
- Alerts as it files. A push when LFST files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut LFST, by share count.
- Ask anything. An AI agent that reads every LFST filing and answers with sources.
LFST alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Bourdon David | G | Sep 22, 2026 | 150,000 | - |
| Bourdon David | G | Sep 22, 2026 | 150,000 | - |
| Bourdon David | G | Sep 22, 2026 | 150,000 | - |
| Bourdon David | G | Sep 22, 2026 | 150,000 | - |
| TPG GP A, LLC | Sell | Sep 11, 2026 | 18,409,705 | $12.29 |
| Paunovich Vukasin | Sell | Sep 2, 2026 | 42,067 | $12.87 |
| Bourdon David | J | Sep 2, 2026 | 150,000 | - |
| Varanakis Ann | F | Aug 24, 2026 | 8,156 | $12.16 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $1.1B | $1.3B | $1.4B |
| Operating Income | -$189.1M | -$31.6M | $24.1M |
| Net Income | -$186.3M | -$57.4M | $9.7M |
| Op. Margin | -17.9% | -2.5% | 1.7% |
| Net Margin | -17.6% | -4.6% | 0.7% |
| Balance Sheet | |||
| Total Assets | $2.1B | $2.1B | $2.2B |
| Equity | - | $1.4B | $1.5B |
| ROE | - | -4.0% | 0.6% |
| Cash Flow | |||
| Operating CF | -$16.9M | $107.3M | $146.2M |
| CapEx | $40.5M | $21.6M | $36.1M |
Source: XBRL data in LifeStance Health Group, Inc. (LFST)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate LFST share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 32 | $1.79B |
| Q1 2026 | 31 | $847.9M |
| Q4 2025 | 27 | $798.4M |
| Q3 2025 | 28 | $557.8M |
| Q2 2025 | 27 | $472.6M |
| Q1 2025 | 24 | $536.7M |
| Q4 2024 | 17 | $479.1M |
| Q3 2024 | 11 | $95.7M |
- BlackRock+18.21M (+100%)
- Vanguard Portfolio Management LLC+4.28M (+44%)
- State Street Corp+4.13M (+101%)
- T. Rowe Price Group+2.62M (+1751%)
- Vanguard Capital Management LLC+1.83M (+23%)
- Citadel Advisors LLC−3.34M (-87%)
- Bank of America Corp−594.7K (-30%)
- FMR LLC (Fidelity)−433.0K (-1%)
- Goldman Sachs Group−274.7K (-13%)
- Citigroup−189.4K (-32%)
- Two Sigma Investments+154.8K
Source: 13F-HR filings on SEC EDGAR (aggregated from 197 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
LFST filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 24, 2026 | - | - | - |
| 4 | Sep 15, 2026 | - | - | - |
| 8-K | Sep 11, 2026 | - | Analysis | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Aug 26, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 14, 2026 | - | - | - |
| 4 | Aug 13, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| SC 13G | Jul 29, 2026 | - | - | |
| 4 | Jul 14, 2026 | - | - | - |
| 8-K | Jul 7, 2026 | - | Analysis | - |
| 4 | Jul 7, 2026 | - | - | - |
| 4 | Jul 7, 2026 | - | - | - |
| 4 | Jul 7, 2026 | - | - | - |
| 4 | Jul 7, 2026 | - | - | - |
| 4 | Jul 7, 2026 | - | - | - |
| 4 | Jul 7, 2026 | - | - | - |
| 4 | Jun 30, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
Related Health Care companies
- DCGO · DocGo Inc.Services-Health Services
- WGS · GeneDx Holdings Corp.Services-Health Services
- INNV · InnovAge Holding Corp.Services-Health Services
- OMDA · Omada Health, Inc.Services-Health Services
- PNTG · Pennant Group, Inc.Services-Health Services
- PRVA · Privia Health Group, Inc.Services-Health Services
- SRTA · Strata Critical Medical, Inc.Services-Health Services
- TALK · Talkspace, Inc.Services-Health Services
LFST SEC filings: frequently asked questions
Are LFST insiders buying or selling?
In the last 90 days, LifeStance Health Group, Inc. (LFST) officers, directors and 10% owners reported no open-market purchases and 8 open-market sales worth $378.8 million by 5 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold LFST stock?
As of June 30, 2026, the largest LifeStance Health Group, Inc. (LFST) holders among the 13F filers tracked by SignalX were FMR LLC (Fidelity) ($623.9 million), BlackRock ($389.3 million), Vanguard Portfolio Management LLC ($149.5 million), Dimensional Fund Advisors ($122.4 million), Vanguard Capital Management LLC ($104.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was LFST's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), LifeStance Health Group, Inc. (LFST) reported revenue of $1.4 billion (up 13.9% from FY2024) and net income of $9.7 million. The figures come from the XBRL data in the 10-K.
What are the main risks in LFST's latest 10-K?
In the 10-K filed February 25, 2026, LifeStance Health Group, Inc. (LFST) flagged: Regulatory risk from the No Surprises Act (effective Jan 1, 2022) causing payment disputes and penalties for billing and provider directory inaccuracies. Geopolitical/macroeconomic exposure from 29% revenue concentration with UnitedHealthcare (14%) and Elevance Health (15%), risking impact from reimbursement changes. (AI summary of the Risk Factors section.)
What did LFST report in its latest 8-K?
LifeStance Health Group, Inc. (LFST) filed an 8-K on September 11, 2026 reporting Item 8.01 (Other Events). Underwritten offering of 22,250,000 LifeStance shares by selling stockholders, closing September 11, 2026.
What are the latest LFST SEC filings?
LifeStance Health Group, Inc. (LFST) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on September 11, 2026 and a Form 4 insider filing on September 24, 2026.
What is LFST's SEC CIK number?
LifeStance Health Group, Inc. (LFST)'s SEC Central Index Key (CIK) is 1845257. EDGAR lists every LFST filing under that number.
Ask anything about LFST
The research agent reads LFST's filings, financials, insider trades and 13F holders, then answers with sources.